Kevin Starr co-architected Third Rock Ventures' company-creation first model, where they identify breakthrough academic science, workshop ideas with scientists for 1-3 years, then build companies from scratch with large initial funding rounds. He has consistently focused on ultra-rare and orphan diseases, helping build category-defining companies like Bluebird Bio, Agios, and Foundation Medicine that tackle previously neglected conditions through advanced gene therapy and precision oncology approaches. Kevin Starr co-architected Third Rock Ventures' company-creation first model, where they identify breakthrough academic science, workshop ideas with scientists for 1-3 years, then build companies from scratch with large initial funding rounds. He has consistently focused on ultra-rare and orphan diseases, helping build category-defining companies like Bluebird Bio, Agios, and Foundation Medicine that tackle previously neglected conditions through advanced gene therapy and precision oncology approaches.